Indegene Limited

BSE: INDGN544172ISIN INE065X01017

Healthcare
Healthcare Research, Analytics & Technology
BSE 500

Share price

₹617.05+3.90 (+0.64%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹638.50
52W low: ₹414.90
Off 52W high: -3.36%
1M return: +3.13%
3M return: +14.17%
6M return: +15.81%
1Y return: +14.61%
20D avg volume: 90,941
50 DMA: ₹591.97
200 DMA: ₹523.85

Key ratios Consolidated

Market cap: ₹14,870 Cr
Current price: ₹617.05
52W high / low: ₹638.50 / ₹414.90
Face value: ₹2.00
P/E: 36.17
P/B: 4.42
EPS (TTM): ₹17.06
Book value / share: ₹139.64
ROE: —
ROCE: 15.40%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-300.80 Cr
Interest cover: 28.20
Dividend yield: 0.36%
Dividend / share (TTM): ₹2.25
Payout: 13.19%
Cash conversion cycle: 83.3 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	1,122	1,063	1,003	942.10	804.20	760.80	755.60	720.40	686.80	676.50	673.00
	15.00	29.00	10.80	19.40	19.70	22.10	25.60	37.70	21.40	22.50	23.20
	1,137	1,092	1,014	961.50	823.90	782.90	781.20	758.10	708.20	699.00	696.20
	989.90	939.40	888.80	826.80	690.80	630.80	631.90	611.80	584.10	579.40	565.10
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	681.70	659.10	632.40	568.00	515.80	481.50	485.10	443.80	442.00	444.30	428.40
	6.90	6.40	7.20	4.60	3.80	3.70	3.10	3.20	4.00	11.70	12.30
	46.40	44.10	41.80	39.60	23.40	21.60	20.70	20.00	19.40	20.10	18.50
	254.90	229.80	207.40	214.60	147.80	124.00	123.00	144.80	118.70	103.30	105.90
	147.40	152.70	125.40	134.70	133.10	152.10	149.30	146.30	124.10	119.60	131.10
	0.00	0.00	-20.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.40
	147.40	152.70	105.10	134.70	133.10	152.10	149.30	146.30	124.10	119.60	133.50
	35.10	36.50	25.40	31.80	31.00	35.70	31.70	36.60	32.40	31.90	38.70
	112.30	116.20	79.70	102.90	102.10	116.40	117.60	109.70	91.70	87.70	94.80
	4.67	4.84	3.32	4.29	4.26	4.86	4.91	4.59	3.84	3.79	4.27
Key metrics
	200.70	203.20	154.10	178.90	160.30	177.40	173.10	169.50	147.50	151.40	164.30
	17.90%	19.10%	15.40%	19.00%	19.90%	23.30%	22.90%	23.50%	21.50%	22.40%	24.40%
	10.00%	10.90%	7.90%	10.90%	12.70%	15.30%	15.60%	15.20%	13.40%	13.00%	14.10%
	4.30%	—	3.20%	—	4.50%	—	5.50%	—	—	—	—
	39.60%	39.70%	32.80%	30.80%	17.10%	12.50%	12.30%	—	—	—	—
	10.00%	-0.20%	-32.20%	-6.20%	11.30%	32.70%	24.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	4,131	3,510	2,839	2,590
	74.20	72.00	107.20	76.30
	4,205	3,582	2,946	2,666
	3,645	3,037	2,407	2,210
	0.00	0.00	0.00	—
	0.00	0.00	0.00	—
	2,541	2,198	1,815	1,652
	25.10	19.30	22.00	49.40
	171.90	126.40	80.20	76.10
	906.70	693.80	489.80	432.60
	560.20	545.30	539.30	456.20
	-20.30	-20.30	0.00	2.40
	539.90	525.00	539.30	458.60
	128.80	123.90	132.60	121.90
	411.10	401.10	406.70	336.70
	17.12	16.72	17.15	15.19
Key metrics
	736.90	670.70	641.50	584.10
	17.84%	19.10%	22.60%	22.60%
	9.95%	11.40%	14.30%	13.00%
	—	15.40%	20.30%	—
	35.84%	23.60%	9.60%	—
	-7.78%	-1.40%	20.80%	—
	—	606.50	411.90	—
	—	1.62	1.09	—
	—	0.00	0.00	—
	—	-300.80	-241.00	—
	—	83.3	84.6	—
Balance sheet
	—	4,620	3,326	—
	—	2,618	2,530	—
	—	300.80	241.00	—
	—	981.80	751.40	—
	—	0.00	0.00	—
	—	138.40	101.70	—
	—	194.00	134.90	—
	—	180.70	93.40	—
	—	1,086	564.50	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	3,139	2,616	—
Cash flow
	—	650.80	441.90	—
	—	-512.40	-682.70	—
	—	-82.60	287.50	—
	—	44.30	30.00	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	368.50	340.70	368.20	290.10	306.70	255.60	266.70	286.70	281.70	258.60	272.50
	23.00	33.90	6.10	22.60	17.50	32.10	35.20	22.30	22.40	13.70	23.10
	391.50	374.60	374.30	312.70	324.20	287.70	301.90	309.00	304.10	272.30	295.60
	313.20	294.60	279.10	263.70	246.70	227.90	235.50	242.90	243.10	227.20	235.20
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	234.80	221.70	213.40	201.90	198.30	181.60	184.50	192.20	197.10	185.30	194.90
	3.40	2.70	3.10	1.80	2.00	1.70	1.50	1.60	1.60	1.50	1.50
	13.10	11.40	10.90	9.50	8.60	7.30	6.90	6.50	6.20	6.60	7.60
	61.90	58.80	51.70	50.50	37.80	37.30	42.60	42.60	38.20	33.80	31.20
	78.30	80.00	95.20	49.00	77.50	59.80	66.40	66.10	61.00	45.10	60.40
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	78.30	80.00	95.20	49.00	77.50	59.80	66.40	66.10	61.00	45.10	60.40
	20.10	20.10	23.10	14.20	17.60	14.70	12.20	16.20	16.20	12.50	11.50
	58.20	59.90	72.10	34.80	59.90	45.10	54.20	49.90	44.80	32.60	48.90
	2.42	2.49	3.00	1.45	2.50	1.88	2.26	2.09	1.88	1.41	2.20
Key metrics
	94.80	94.10	109.20	60.30	88.10	68.80	74.80	74.20	68.80	53.20	69.50
	25.70%	27.60%	29.70%	20.80%	28.70%	26.90%	28.00%	25.90%	24.40%	20.60%	25.50%
	15.80%	17.60%	19.60%	12.00%	19.50%	17.60%	20.30%	17.40%	15.90%	12.60%	17.90%
	3.60%	—	4.50%	—	3.90%	—	3.50%	—	—	—	—
	20.10%	33.30%	38.10%	1.20%	8.90%	-1.20%	-2.10%	—	—	—	—
	-2.80%	32.80%	33.00%	-30.30%	33.70%	38.30%	10.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	1,368	1,221	1,094	1,046
	85.60	78.30	90.40	50.30
	1,453	1,299	1,184	1,096
	1,151	1,018	945.50	915.30
	0.00	0.00	0.00	—
	0.00	0.00	0.00	—
	871.80	795.20	759.20	752.30
	11.00	8.70	6.20	6.60
	44.90	36.30	26.20	31.10
	222.90	177.30	153.90	125.30
	302.50	281.40	238.50	180.60
	0.00	0.00	0.00	—
	302.50	281.40	238.50	180.60
	77.50	69.50	57.20	42.70
	225.00	211.90	181.30	137.90
	9.36	8.83	7.64	6.22
Key metrics
	358.40	326.40	270.90	218.30
	26.21%	26.70%	24.80%	20.90%
	16.45%	17.40%	16.60%	13.20%
	—	13.10%	12.50%	—
	22.57%	11.60%	4.60%	—
	7.60%	16.90%	31.50%	—
	—	301.50	112.50	—
	—	1.63	0.71	—
	—	0.00	0.00	—
	—	-48.50	-35.20	—
	—	76.5	128.0	—
Balance sheet
	—	2,482	2,150	—
	—	1,275	1,218	—
	—	48.50	35.20	—
	—	288.40	418.40	—
	—	0.00	0.00	—
	—	81.90	59.60	—
	—	112.60	52.80	—
	—	32.60	34.80	—
	—	273.80	189.50	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	2,080	1,888	—
Cash flow
	—	345.60	129.00	—
	—	-272.10	-824.70	—
	—	-62.60	717.30	—
	—	44.10	16.50	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +22.57%
Profit YoY (TTM): +7.60%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +35.84%
Profit YoY (TTM): -7.78%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 0.00%

Quarter	September 2026	June 2026
Promoter %	0.00%	0.00%

Holder	Type	Holding	Previous	Change
NADATHUR FAREAST PTE LTD	Public	21.87%	21.87%	0.00%
Manish Gupta	Public	8.91%	8.91%	0.00%
Rajesh Bhaskaran Nair	Public	7.14%	7.14%	0.00%
Sanjay S Parikh	Public	4.98%	4.98%	0.00%
QUANT MUTUAL FUND - QSIF EQUITY LONG SHORT FUND	Public	4.68%	—	—
ICICI PRUDENTIAL TECHNOLOGY FUND	Public	3.11%	1.19%	+1.92%
Government Pension Fund Global	Public	2.77%	2.57%	+0.20%
Gaurav Kapoor	Public	2.60%	2.60%	0.00%
Vida Trustees Private Limited	Public	2.32%	2.32%	0.00%
Anand Kiran	Public	2.16%	2.16%	0.00%
Aarabhi Partners Consultants Llp	Public	2.09%	2.09%	0.00%
SUNDARAM MUTUAL FUND - SUNDARAM AGGRESSIVE HYBRID FUND	Public	1.94%	—	—
Sycamore Philanthropy (Ptc) Limited	Public	1.43%	1.43%	0.00%
Chestnut Associates Ptc Limited	Public	1.43%	1.43%	0.00%
Fidelity Funds - India Focus Fund	Public	1.34%	1.50%	-0.16%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Syngene International Limited	16,841	417.20	90.49	8.40%	-5.99% TTM	-60.25% TTM	-35.44%
Indegene Limited	14,870	617.05	36.17	15.40%	+35.84% TTM	-7.78% TTM	+14.61%
Suven Life Sciences Ltd.	7,803	276.15	-22.14	-46.50%	+17.29% TTM	-91.30% TTM	+40.18%
Vimta Labs Ltd.	2,230	498.80	—	—	+4.90% TTM	+48.48% TTM	-24.58%
NOVELIX PHARMACEUTICALS LIMITED S	194	68.00	53.54	6.70%	+179.89% TTM	+535.09% TTM	+29.52%
Bilcare Ltd.	183	77.69	16.51	9.20%	+11.44% TTM	+125.02% TTM	-25.62%
TAKE LIMITED S	170	11.47	29.00	11.10%	-15.35% TTM	+124.35% TTM	-52.11%
Jeevan Scientific Technology Limited	164	81.70	32.02	4.80%	+66.05% TTM	+222.49% TTM	+30.72%
GlobalSpace Technologies Limited	99	28.84	29.21	5.00%	+37.21% TTM	+398.53% TTM	+63.12%
Adeshwar Meditex Limited S	27	18.80	21.36	6.00%	—	—	+1.62%
Vanta Bioscience Limited	14	20.39	—	1.50%	—	—	-5.86%

Filings & corporate actions

Recent announcements

Transcript of the Q2 FY27 Earnings Call3 Nov 2026 · Company Update / Earnings Call Transcript
Intimation of Newspaper Publication31 Oct 2026 · Company Update / Newspaper Publication
Audio Recording of the Q2 FY27 Earnings Call30 Oct 2026 · Company Update / Analyst / Investor Meet
Audio Recording of the Q2 FY27 Earnings Call30 Oct 2026 · Company Update / Analyst / Investor Meet
Analyst Presentation and Fact Sheet - financial results for the 2nd quarter and half year ended 30th September, 202629 Oct 2026 · Company Update / Investor Presentation
Press Release29 Oct 2026 · Company Update / Press Release / Media Release
Intimation of Resignation of Ms. Srishti Ramesh Kaushik (M. No A21609) from the position of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company.29 Oct 2026 · Company Update / Resignation of Company Secretary / Compliance Officer
Allotment of shares under RSU Scheme 2020 and ESOP Scheme 202029 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Unaudited Financial Results for the 2nd quarter and half year ended 30th September 202629 Oct 2026 · Result / Financial Results
Outcome of the Board Meeting29 Oct 2026 · Board Meeting / Outcome of Board Meeting
Acquisition26 Oct 2026 · Company Update / Acquisition
Press Release22 Oct 2026 · Company Update / Press Release / Media Release
Resignation of Mr. Mark Francis Dzialga (DIN: 00955485) from the position of Non-Executive Non Independent Director of the Company15 Oct 2026 · Company Update / Resignation of Director
Certificate under Regulation 74 (5) of SEBI DP Regulations, 20188 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Allotment of ESOP shares8 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Press Release6 Oct 2026 · Company Update / Press Release / Media Release
Intimation of Indegene Limited Q2 FY27 Earnings Call30 Sep 2026 · Company Update / Analyst / Investor Meet
Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....30 Sep 2026 · Board Meeting / Board Meeting
Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Press Release23 Sep 2026 · Company Update / Press Release / Media Release
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015 - Merger of Indirect Wholly owned subsidiaries of the Company in Germany10 Sep 2026 · Company Update / Restructuring
Intimation of Investors / Analysts Meeting8 Sep 2026 · Company Update / Analyst / Investor Meet
Update on Material Litigation under the Telephone Consumer Protection Act, 1991 involving Wholly- Owned Subsidiary, Indegene, Inc.31 Aug 2026 · Company Update / General
Intimation of Investors / Analysts Meeting19 Aug 2026 · Company Update / Analyst / Investor Meet
Update on Material Litigation under the Telephone Consumer Protection Act, 1991 involving Wholly-Owned Subsidiary, Indegene, Inc.19 Aug 2026 · Company Update / General
Transcript of the 28th Annual General Meeting held on August 13, 202617 Aug 2026 · AGM/EGM / AGM
Appointment of Ms. Jill Mary De Simone (DIN: 11483134) as an independent Director of the Company17 Aug 2026 · Company Update / Change in Directorate
Scrutinizer''s Report - 28th Annual General Meeting17 Aug 2026 · AGM/EGM / AGM
Intimation of Investors / Analysts Meeting14 Aug 2026 · Company Update / Analyst / Investor Meet
Proceedings of the 28th Annual General Meeting of the Company13 Aug 2026 · AGM/EGM / AGM
Intimation of Investors / Analysts Meeting12 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of Investors / Analysts Meeting12 Aug 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I- A SPV Ltd10 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I SPV Ltd10 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Transcript of earnings conference call on financial results for the quarter ended June 30, 20266 Aug 2026 · Company Update / Earnings Call Transcript
Intimation of Newspaper Publication1 Aug 2026 · Company Update / Newspaper Publication
Audio Recording of the Q1 FY27 Earnings Call31 Jul 2026 · Company Update / Analyst / Investor Meet
Analyst Presentation and fact sheet - financial results for the quarter ended June 30, 202630 Jul 2026 · Company Update / Investor Presentation
Press Release30 Jul 2026 · Company Update / Press Release / Media Release
Monitoring Agency Report30 Jul 2026 · Company Update / Monitoring Agency Report

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 2.2500	31 Jul 2026	31 Jul 2026	—
Final Dividend - Rs. - 2.0000	13 Jun 2025	13 Jun 2025	—

Board meetings

29 Oct 2026 Board Meeting - Financial Results
30 Jul 2026 Board Meeting - Financial Results